
FDA approves Rasonque for pancreatic cancer, offering extended survival
The story in brief
The FDA approved the pancreatic cancer drug Rasonque, developed by Revolution Medicines, which extends median survival to 13.2 months compared to 6.7 months with chemotherapy. The approval came six months ahead of schedule, allowing expanded access for patients with metastatic cancer that had stopped responding to prior treatment. The drug targets RAS gene mutations and has fewer severe side effects than traditional chemotherapy.